AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12093837 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinical feel method)
Number of subjects: 640
Study 10214534 — intervention group
Group type: EXPERIMENTAL
Intervention: Avitriptan 150 mg
Number of subjects: 20
Study 10214534 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 20
Study 10214534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10214534 — intervention group
Group type: EXPERIMENTAL
Intervention: Avitriptan 75 mg
Number of subjects: 20
Study 8848532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 41-3696 (1, 3, 5 and 10 mg)
Number of subjects: 12
Study 8848532 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 12
Study 8848532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8848532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 41-3696 (5 and 10 mg)
Number of subjects: 12
Study 8848532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 41-3696 (up to 5 mg)
Number of subjects: 12
Study 2088202 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-aluminum hydroxide (MAH) 15 ml
Number of subjects: 32
Study 2088202 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CC) 5 ml
Number of subjects: 32
Study 2088202 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin alone
Number of subjects: 32
Study 74281 — intervention group
Group type: EXPERIMENTAL
Intervention: BACON (bleomycin, adriamycin, CCNU, vincristine, mechlorethamine)
Number of subjects: 231
Study 74281 — intervention group
Group type: COMPARATOR
Intervention: NAC (mechlorethamine, adriamycin, CCNU)
Number of subjects: 231
Study 74281 — intervention group
Group type: EXPERIMENTAL
Intervention: BACON (for PS 8-10)
Number of subjects: 231
Study 74281 — intervention group
Group type: COMPARATOR
Intervention: NAC (for PS 8-10)
Number of subjects: 231
Study 74281 — intervention group
Group type: EXPERIMENTAL
Intervention: BACON (for PS 5-7)
Number of subjects: 231
Study 74281 — intervention group
Group type: COMPARATOR
Intervention: NAC (for PS 5-7)
Number of subjects: 231
Study 74281 — intervention group
Group type: EXPERIMENTAL
Intervention: BACON (for PS 1-4)
Number of subjects: 231
Study 74281 — intervention group
Group type: COMPARATOR
Intervention: NAC (for PS 1-4)
Number of subjects: 231
Study 74281 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who responded or improved (regardless of PS)
Number of subjects: 231
Study 31344520 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Learning Collaborative (VLC) - 18-month intensive group-based with monthly learning sessions
Number of subjects: 48
Study 31344520 — intervention group
Group type: COMPARATOR
Intervention: Individual technical assistance - four scheduled conference calls over 18 months
Number of subjects: 48
Study 31344520 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Learning Collaborative (VLC)
Number of subjects: 48
Study 31344520 — intervention group
Group type: COMPARATOR
Intervention: Individual technical assistance
Number of subjects: 48
Study 28464343 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action (20 mL after meals and bedtime)
Number of subjects: 314
Study 28464343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mL after meals and bedtime)
Number of subjects: 314
Study 25410648 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐L polyethylene glycol with ascorbic acid (2‐L PEG/Asc)
Number of subjects: 388
Study 25410648 — intervention group
Group type: COMPARATOR
Intervention: Sodium picosulfate with magnesium citrate (SP/MC)
Number of subjects: 388
Study 23799903 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttonhole cannulation
Number of subjects: 104
Study 23799903 — intervention group
Group type: COMPARATOR
Intervention: Rope-ladder cannulation
Number of subjects: 104
Study 21316048 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 5 mg
Number of subjects: 194
Study 21316048 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg
Number of subjects: 194
Study 21316048 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 20 mg
Number of subjects: 194
Study 21316048 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 30 mg
Number of subjects: 194
Study 21316048 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 50 mg/d
Number of subjects: 194
Study 19231337 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT on
Number of subjects: 15
Study 19231337 — intervention group
Group type: COMPARATOR
Intervention: CRT off
Number of subjects: 15
Study 16875507 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 157
Study 16875507 — intervention group
Group type: EXPERIMENTAL
Intervention: All-round functional-skills training
Number of subjects: 157
Study 16875507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both resistance and functional-skills training
Number of subjects: 157
Study 16875507 — intervention group
Group type: COMPARATOR
Intervention: Educational control condition
Number of subjects: 157
Study 12915798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose solution (2 mL)
Number of subjects: 34
Study 12915798 — intervention group
Group type: COMPARATOR
Intervention: Water (2 mL)
Number of subjects: 34
Study 10852774 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 12
Study 10852774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9024474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer support groups (CSGs) with coaching
Number of subjects: 181
Study 9024474 — intervention group
Group type: COMPARATOR
Intervention: Cancer support groups (CSGs) without coaching
Number of subjects: 181
Study 9024474 — intervention group
Group type: EXPERIMENTAL
Intervention: CSGs (both with and without coaching)
Number of subjects: 181
Study 1393035 — intervention group
Group type: EXPERIMENTAL
Intervention: salcatonin 200 IU
Number of subjects: 208
Study 1393035 — intervention group
Group type: COMPARATOR
Intervention: calcium (placebo)
Number of subjects: 208
Study 1393035 — intervention group
Group type: EXPERIMENTAL
Intervention: salcatonin
Number of subjects: 208
Study 3930143 — intervention group
Group type: EXPERIMENTAL
Intervention: Four levonorgestrel covered rods
Number of subjects: 146
Study 3930143 — intervention group
Group type: EXPERIMENTAL
Intervention: Six levonorgestrel covered rods
Number of subjects: 146
Study 3930143 — intervention group
Group type: COMPARATOR
Intervention: Non-hormonal contraceptors (Control)
Number of subjects: 146
Study 31902455 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote-access CT scanner (RA) with peer-assisted learning (PAL)
Number of subjects: 62
Study 31902455 — intervention group
Group type: COMPARATOR
Intervention: Local-access CT scanner (LA) facilitated by a CT radiographer
Number of subjects: 62
Study 30395266 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI with ovarian stimulation (IUI-OS)
Number of subjects: 1896
Study 30395266 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1896
Study 28226308 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) for weight loss
Number of subjects: 74
Study 28226308 — intervention group
Group type: COMPARATOR
Intervention: Attentional control
Number of subjects: 74
Study 28226308 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 74
Study 28226308 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with BED
Number of subjects: 74
Study 28226308 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants without BED
Number of subjects: 74
Study 25733516 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified recombinant LppQ‐N' formulated in Freund's adjuvant
Number of subjects: 0
Study 25733516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24899755 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 85
Study 24899755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 24899755 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg/day
Number of subjects: 85
Study 21976367 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg) every 6 months for 3 years
Number of subjects: 7808
Study 21976367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808
Study 20176737 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg GH/m(2) per day
Number of subjects: 41
Study 20176737 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg GH/m(2) per day
Number of subjects: 41
Study 20176737 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 41
Study 17954798 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose reteplase
Number of subjects: 0
Study 17954798 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose abciximab plus half-dose reteplase
Number of subjects: 0
Study 16279158 — intervention group
Group type: COMPARATOR
Intervention: Home oxygen therapy (HOT)
Number of subjects: 170
Study 11990447 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable barrier (polyglactin 910; test: T)
Number of subjects: 12
Study 11990447 — intervention group
Group type: COMPARATOR
Intervention: Non-resorbable barrier (expanded polytetrafluoroethylene [ePTFE]; control: C)
Number of subjects: 12
Study 11990447 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 12
Study 10440620 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg loading dose, followed by 200 mg once daily for 10 days)
Number of subjects: 298
Study 10440620 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (500 mg twice daily for 10 days)
Number of subjects: 298
Study 10440620 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 298
Study 10440620 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 298
Study 7784810 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine penicillin 100,000 IU (PP100)
Number of subjects: 184
Study 7784810 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine penicillin 200,000 IU (PP200)
Number of subjects: 184
Study 7784810 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine penicillin 400,000 IU (PP400)
Number of subjects: 184
Study 7784810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg (TTC)
Number of subjects: 184
Study 7784810 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall case fatality rate
Number of subjects: 184
Study 1982108 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine at bedtime
Number of subjects: 101
Study 1982108 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg nizatidine BID
Number of subjects: 101
Study 1982108 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine BID
Number of subjects: 101
Study 538813 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of long-acting chloramphenicol (Tifomycine)
Number of subjects: 131
Study 538813 — intervention group
Group type: COMPARATOR
Intervention: Five-day course of crystalline and procaine penicillin
Number of subjects: 131
Study 31815705 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (2000 pulses; 20 Hz; 90% RMT; 10 trains of 10 s with 25 s between each train) for 10 days followed by 5 booster sessions every month for 3 months
Number of subjects: 33
Study 31815705 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 33
Study 31134354 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg positive samples
Number of subjects: 492
Study 31134354 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HBs positive samples
Number of subjects: 492
Study 31134354 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HBc positive samples
Number of subjects: 492
Study 31134354 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HDV positive samples
Number of subjects: 492
Study 31134354 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HCV positive samples
Number of subjects: 492
Study 31134354 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HIV-1 positive samples
Number of subjects: 492
Study 31134354 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HTLV I/II positive samples
Number of subjects: 492
Study 28135143 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus Etoposide (arm A)
Number of subjects: 204
Study 28135143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus Etoposide with Bevacizumab (arm B)
Number of subjects: 204
Study 27053392 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-transfusion from the drain (RTF2)
Number of subjects: 101
Study 27053392 — intervention group
Group type: COMPARATOR
Intervention: Standard drainage (DRN2)
Number of subjects: 101
Study 27053392 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-transfusion from the drain (RTF)
Number of subjects: 101
Study 27053392 — intervention group
Group type: COMPARATOR
Intervention: Standard drainage (DRN)
Number of subjects: 101
Study 24077206 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (200 mg/day)
Number of subjects: 77
Study 24077206 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (any dose)
Number of subjects: 77
Study 24077206 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 77
Study 24077206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 21427644 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intergenerational volunteering intervention (hour-long sessions with kindergarten and older elementary classes for 5 months)
Number of subjects: 15
Study 21427644 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 19139382 — intervention group
Group type: EXPERIMENTAL
Intervention: Good health status (KCCQ scores > or =75)
Number of subjects: 1516
Study 19139382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fair health status (KCCQ, 50 to 74)
Number of subjects: 1516
Study 19139382 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor health status (KCCQ, 25 to 49)
Number of subjects: 1516
Study 17495195 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band surgical program
Number of subjects: 61
Study 17495195 — intervention group
Group type: COMPARATOR
Intervention: Medical program using a very-low-energy diet and orlistat
Number of subjects: 61
Study 15709844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 15709844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive changes in pregain sessions
Number of subjects: 0
Study 12122526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine infusion (up to 2 mcg/kg/min for up to 7 days)
Number of subjects: 102
Study 12122526 — intervention group
Group type: COMPARATOR
Intervention: Control (no dopexamine infusion)
Number of subjects: 102
Study 10220637 — intervention group
Group type: EXPERIMENTAL
Intervention: Syncope alone
Number of subjects: 486
Study 10220637 — intervention group
Group type: EXPERIMENTAL
Intervention: Syncope with ventricular tachycardia
Number of subjects: 486
Study 10220637 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventricular tachycardia
Number of subjects: 486
Study 10220637 — intervention group
Group type: COMPARATOR
Intervention: Ventricular fibrillation
Number of subjects: 486
Study 7570898 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and treatment programme for imported intestinal parasites
Number of subjects: 0
Study 7570898 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2195860 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol, 200 mg twice daily
Number of subjects: 607
Study 2195860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607
Study 2195860 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 607
Study 428086 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg q.a.m.
Number of subjects: 84
Study 428086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 428086 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (normal PRA EHT subgroup)
Number of subjects: 84
Study 31604115 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of CCL2
Number of subjects: 0
Study 31604115 — intervention group
Group type: COMPARATOR
Intervention: High CCL2 expression
Number of subjects: 0
Study 30238517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented lithium disilicate crown on a customized zirconia abutment (CEM)
Number of subjects: 33
Study 30238517 — intervention group
Group type: COMPARATOR
Intervention: Screw‐retained crown with a directly veneered zirconia abutment (SCREW)
Number of subjects: 33
Study 27733398 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency physical activity (HF): 50 min/d, 6 d/wk (300 min/wk)
Number of subjects: 75
Study 27733398 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency physical activity (LF): 100 min/d, 3 d/wk (300 min/wk)
Number of subjects: 75
Study 24821476 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter hyperintensity volume
Number of subjects: 332
Study 24821476 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E ε4 status
Number of subjects: 332
Study 24821476 — intervention group
Group type: EXPERIMENTAL
Intervention: Entorhinal cortex volume (ECV)
Number of subjects: 332
Study 24821476 — intervention group
Group type: EXPERIMENTAL
Intervention: High ECV and low WMH
Number of subjects: 332
Study 24821476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination score decline of 3 or more points over 6 months or 6 or more points over 12 months
Number of subjects: 332
Study 22543316 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week conditioning programme comprising two 1-hr sessions of circuit and vibration training per week
Number of subjects: 24
Study 22543316 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 20524934 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and telmisartan (ARB) for 12 months
Number of subjects: 66
Study 20524934 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and enalapril (ACEI) for 12 months
Number of subjects: 66
Study 20524934 — intervention group
Group type: COMPARATOR
Intervention: CAD group (baseline)
Number of subjects: 66
Study 20524934 — intervention group
Group type: COMPARATOR
Intervention: High levels of miR-146a and TLR4 mRNA/TLR4 protein at baseline
Number of subjects: 66
Study 17506741 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body forced‐air warming (Bair Hugger, Augustine Medical model 500/OR)
Number of subjects: 60
Study 17506741 — intervention group
Group type: COMPARATOR
Intervention: Electric heating pad (Operatherm 202, KanMed)
Number of subjects: 60
Study 15669892 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine (400 mg/day)
Number of subjects: 38
Study 15669892 — intervention group
Group type: COMPARATOR
Intervention: risperidone (4 mg/day)
Number of subjects: 38
Study 15669892 — intervention group
Group type: COMPARATOR
Intervention: fluphenazine (12.5 mg/day)
Number of subjects: 38
Study 12691536 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 2302 (antisense phosphorothioate oligonucleotide) at a fixed dose regimen of 250-400 mg, given three times weekly
Number of subjects: 150
Study 12691536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 10496186 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant IFN beta‐1a (Rebif, Ares‐Serono) 22 microg once a week (QW)
Number of subjects: 0
Study 10496186 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant IFN beta‐1a (Rebif, Ares‐Serono) 22 microg three times a week
Number of subjects: 0
Study 10496186 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant IFN beta‐1a (Rebif, Ares‐Serono) 66 microg once a week (QW)
Number of subjects: 0
Study 10496186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9150968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold provocation at 10 degrees C on the fifth finger of one hand.
Number of subjects: 12
Study 9150968 — intervention group
Group type: COMPARATOR
Intervention: Systolic pressures measured in air of four fingers of both hands and both arms.
Number of subjects: 12
Study 2269924 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine and hydrocortisone cream 1% (used in combination)
Number of subjects: 0
Study 2269924 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine
Number of subjects: 0
Study 2269924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone cream 1%
Number of subjects: 0
Study 2269924 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of silver sulfadiazine and hydrocortisone cream
Number of subjects: 0
Study 6102442 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 20 mg tid
Number of subjects: 0
Study 6102442 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine maleate 4 mg tid
Number of subjects: 0
Study 6102442 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (up to 200 mg tid)
Number of subjects: 0
Study 31093925 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-initiated behavioral weight loss intervention
Number of subjects: 248
Study 30926188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided insertion
Number of subjects: 1174
Study 30926188 — intervention group
Group type: COMPARATOR
Intervention: Landmark insertion
Number of subjects: 1174
Study 27893267 — intervention group
Group type: EXPERIMENTAL
Intervention: Online expressive writing intervention
Number of subjects: 100
Study 27893267 — intervention group
Group type: EXPERIMENTAL
Intervention: Active duty deployment
Number of subjects: 100
Study 27893267 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserves or National Guard deployment
Number of subjects: 100
Study 25769593 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70
Study 25769593 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 70
Study 23282124 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80‐320 mg) with bedtime dosing
Number of subjects: 60